Sean Aylmer speaks with Dr Gavriel Schneider, CEO of the Risk 2 Solutions Group, about the psychology of risk, and how businesses can come through challenging times stronger.

Sean Aylmer speaks with Dr Gavriel Schneider, CEO of the Risk 2 Solutions Group, about the psychology of risk, and how businesses can come through challenging times stronger.

Business news you can use. A daily business news podcast with journalists Sean Aylmer and Michael Thompson. Find out more at https://fearandgreed.com.au

Business news you can use. A daily business news podcast with journalists <a href="https://www.linkedin.com/in/sean-aylmer-9922068/" data-saferedirecturl="https://www.google.com/url?q=https://www.linkedin.com/in/sean-aylmer-9922068/&amp;source=gmail&amp;ust=1689199223540000&amp;usg=AOvVaw0wu3ezGEfBZFYspJbTTaYL">Sean Aylmer</a>&nbsp;and&nbsp;<a href="https://www.linkedin.com/in/mcwthompson/" data-saferedirecturl="https://www.google.com/url?q=https://www.linkedin.com/in/mcwthompson/&amp;source=gmail&amp;ust=1689199223540000&amp;usg=AOvVaw08pZ8jZ88rHJgCfbHkTr5k">Michael Thompson</a>.&nbsp;Find out more at&nbsp;<a href="https://protect-au.mimecast.com/s/7AmQCOMxmAtl5q0qiE-KY7?domain=fearandgreed.com.au/" data-saferedirecturl="https://www.google.com/url?q=https://protect-au.mimecast.com/s/7AmQCOMxmAtl5q0qiE-KY7?domain%3Dfearandgreed.com.au/&amp;source=gmail&amp;ust=1689199223540000&amp;usg=AOvVaw1DLq_FuqjEt3HC-ZK1704H">https://fearandgreed.com.au</a>

Fear and Greed is Australia's most popular business podcast.

FEAR & GREED | Business News

Daily business news for people who make their own decisions, with business journalist Sean Aylmer and Michael Thompson. Find out more at https://fearandgreed.com.au

Daily business news for people who make their own decisions, with business journalist <a href="https://www.linkedin.com/in/sean-aylmer-9922068/">Sean Aylmer</a> and <a href="https://www.linkedin.com/in/mcwthompson/">Michael Thompson</a>. Find out more at <a href="https://protect-au.mimecast.com/s/7AmQCOMxmAtl5q0qiE-KY7?domain=fearandgreed.com.au/">https://fearandgreed.com.au</a>

Bonus content - extended interview with Dr Gavriel Schneider

This is the Fear and Greed Afternoon Report - everything you need to know about what happened in the markets, economy and world of business today, in just a few minutes.


ASX hits another record


RBA Governor on inflation


Diplomat families told to leave Middle East


Results wrap


NVIDIA’s massive profit

Join our free daily newsletter here.

This is the&nbsp;<a href="https://fearandgreed.com.au/">Fear and Greed</a> Afternoon Report - everything you need to know about what happened in the markets, economy and world of business today, in just a few minutes.
<ol>
<li data-start="0" data-end="42">
ASX hits another record
</li>
<li data-start="0" data-end="42">
RBA Governor on inflation
</li>
<li data-start="0" data-end="42">
Diplomat families told to leave Middle East
</li>
<li data-start="135" data-end="176">
Results wrap
</li>
<li data-start="178" data-end="218" data-is-last-node="">
NVIDIA&rsquo;s massive profit
</li>
</ol>
Join our <a href="https://fearandgreed.com.au/newsletter-signup">free daily newsletter here</a>.

Afternoon Report | ASX hits another record

https://api.omny.fm/orgs/2fb3740d-3436-44af-8cc0-a91900716aa5/clips/c7a09f90-ba9f-4aba-9602-b3fd0063b7bc/transcript

Thursday 26 February 2026

Higher than expected inflation figures have upped the chance of an interest rate hike in coming months. 
The local sharemarket hits an all-time high
A bumper profit at Woolworths sends its share price up the most in 30 years 
AI bites, with WiseTech Global to cut 2,000 jobs
Donald Trump’s loud, abrasive State of the Union address

Join our free daily newsletter here.

And don’t miss the latest episode of How Do They Afford That? - this week, starting from scratch with money. Get the episode from APPLE, SPOTIFY, or anywhere you listen to podcasts.

Thursday 26 February 2026
Higher than expected inflation figures have upped the chance of an interest rate hike in coming months.&nbsp;
<ul>
<li aria-level="1">The local sharemarket hits an all-time high</li>
<li aria-level="1">A bumper profit at Woolworths sends its share price up the most in 30 years&nbsp;</li>
<li aria-level="1">AI bites, with WiseTech Global to cut 2,000 jobs</li>
<li aria-level="1">Donald Trump&rsquo;s loud, abrasive State of the Union address</li>
</ul>
Join our<a href="https://fearandgreed.com.au/newsletter-signup"> free daily newsletter here</a>.
And don&rsquo;t miss the latest episode of<a href="https://fearandgreed.com.au/how-do-they-afford-that-sugar-mamma-canna-campbell/"> How Do They Afford That?</a> - this week, starting from scratch with money. Get the episode from<a href="https://podcasts.apple.com/au/podcast/how-do-they-afford-that/id1644255235"> APPLE</a>,<a href="https://open.spotify.com/show/1EW5WRlRh7MovSBNkk6dG8?si=b2203ec2fa934a14"> SPOTIFY</a>, or anywhere you listen to podcasts.

Rate hike likely after CPI surprise; ASX record high; Trump’s rollicking State of the Union

https://api.omny.fm/orgs/2fb3740d-3436-44af-8cc0-a91900716aa5/clips/79ab8610-8ad0-45d4-a6c1-b3fc00b4c675/transcript

Biotech company Imugene reported its half-year results yesterday. It’s still loss-making, but sharply cutting costs and seeing what appear to be genuinely encouraging clinical results.

Its lead cancer therapy, azer-cel, is showing strong response rates in difficult lymphoma cases, with some patients cancer-free for nearly two years - and the FDA has given positive feedback on the company’s strategy.

But at the same time, the company’s share price is down around 80pc over the last year.

Sean Aylmer speaks to Leslie Chong, CEO and Managing Director of Imugene, about what it takes to run a long-cycle biotech business, trying to develop life-changing treatments while keeping investors engaged.

Biotech company Imugene reported its half-year results yesterday. It&rsquo;s still loss-making, but sharply cutting costs and seeing what appear to be genuinely encouraging clinical results. Its lead cancer therapy, azer-cel, is showing strong response rates in difficult lymphoma cases, with some patients cancer-free for nearly two years - and the FDA has given positive feedback on the company&rsquo;s strategy. But at the same time, the company&rsquo;s share price is down around 80pc over the last year. Sean Aylmer speaks to Leslie Chong, CEO and Managing Director of Imugene, about what it takes to run a long-cycle biotech business, trying to develop life-changing treatments while keeping investors engaged.

Q+A: How this biotech CEO keeps the faith in a cancer cure

https://api.omny.fm/orgs/2fb3740d-3436-44af-8cc0-a91900716aa5/clips/f2322d33-add0-479b-8ccd-b3fc00b4c2db/transcript

Bonus content - extended interview with Dr Gavriel Schneider

In 1 playlist(s)

FEAR & GREED | Business News

Social links

Follow podcast

Recent clips